Part of UCB Holdings, Inc.
Clinical Trials
0
0 active
Approvals
25
Total approvals
Agencies
1
Regulatory bodies
Founded
1987
No trial phase data available
No trial data available
No trial data available
- MSD (Merck & Co.) has secured non-exclusive global rights to Cyprumed's oral peptide delivery platform, potentially transforming injectable peptide treatments into convenient tablet formulations. - The agreement includes up to $493 million in milestone payments and grants MSD options for exclusive licensing of the technology for specific targets, with MSD leading all development and commercialization efforts. - Cyprumed's innovative tablet formulation technology offers superior bioavailability using approved pharmaceutical excipients, potentially advancing MSD's macrocyclic peptide portfolio including enlicitide decanoate and efinopegdutide.
- UCB's Bimzelx Navigate program offers bridge access to therapy at $15 per dose for up to 2 years, addressing insurance coverage delays for commercially insured patients. - The program features a dedicated nurse navigator system providing personalized support for insurance, injection training, and emotional support, while maintaining connection with treating physicians. - A digital patient portal and copay assistance program reducing costs to $5 per dose for eligible patients complete the holistic support ecosystem.
